Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab

Patients treated with B-cell-targeting therapies like Rituximab or Ibrutinib have decreased serological response to various vaccines. In this study, we tested serological and cellular response to SARS-CoV-2 mRNA vaccines in 16 patients treated with Ibrutinib, 16 treated with maintenance Rituximab, 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Bacova, Barbora, Kohutova, Zuzana, Zubata, Ivana, Gaherova, Lubica, Kucera, Petr, Heizer, Tomas, Mikesova, Marcela, Karel, Tomas, Novak, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963888/
https://www.ncbi.nlm.nih.gov/pubmed/35352210
http://dx.doi.org/10.1007/s10238-022-00809-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963888/
https://www.ncbi.nlm.nih.gov/pubmed/35352210
http://dx.doi.org/10.1007/s10238-022-00809-0

Ejemplares similares